FKTN and neuromuscular disease caused by qualitative or quantitative defects of alpha-dystroglycan: Inhibition of mTORC1 by rapamycin improves muscle pathology in the fukutin-deficient mouse model of dystroglycanopathy (Foltz et al., 2016) and the mdx mouse model of Duchenne muscular dystrophy (Eghtesad et al., 2011).